Company / Gross Profit
Fulgent Genetics, Inc. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$130.9M
FY2025
5-year range
$18.4M / $777.1M
FY2021-FY2025
Trend
+22.1%
vs FY2024
Sector context
#92 of 100
Health Care
What the data says
Among 100 Health Care companies, Fulgent Genetics, Inc. is in the bottom 8% for gross profit. Gross Profit has fluctuated over the past 10 years, ranging from $342,000 in FY2016 to $777M in FY2023.
Based on SEC 10-K filings.
$131M in FY2025 with a 5-year CAGR of -17.0%.
Declined from $777M to $131M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -26.7%
- 5-Year CAGR
- -17.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 100This company $130.9M Sector average $1.8B
▼
-92.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.0%, indicating a declining trend.
- In FY2025, gross profit increased 22.1% year-over-year.
- Ranks #92 out of 100 companies in the Health Care sector.
- Peak gross profit was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $130.9M | +22.1% |
| FY2024 | $107.2M | -86.2% |
| FY2023 | $777.1M | +134.1% |
| FY2022 | $331.9M | +1701.8% |
| FY2021 | $18.4M | -94.4% |
| FY2020 | $331.9M | +3015.3% |
| FY2019 | $10.7M | +4.7% |
| FY2018 | $10.2M | +0.0% |
| FY2017 | $10.2M | +2876.3% |
| FY2016 | $342.0K | -92.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026